Skip to main content

Dysport®/Xeomin®

Home|Injectables|Dysport®/Xeomin®

Dysport®

Dysport® (abobotulinum toxinA) by Galerma Laboratories, is a relaxer made from a strain of botunlinum toxin type A.  Dysport® was initially submitted to the FDA under the name Reloxin. In addition to functional uses such as cervical dystonia and spasticity, Dysport® is FDA approved for treatment of moderate to severe glabellar lines associated with procerus and corrugator muscular activity in adults under the age of 65.  Dysport® has subtle therapeutic differences from other relaxers but it is our belief that onset of action is more rapid and its effects can even be seen on the day of injection.

At Total Aesthetics, Dysport® has an important role in treatment of patients who are resistant to other neuromodulators such as BOTOX® Cosmetic.

What are the Aesthetic Goals of Dysport® and Xeomin® at Total Aesthetics™?

As one of the most experienced and sought after injectors in New England, Dr. O’Connell’s goal with all relaxers is to achieve a confident, natural and rested look without the artificial, shiny or wooden appearance of an excessively treated forehead. Dr. O’Connell prefers his patients to have some residual natural brow motion without an inanimate glabellar complex and with a natural appearing smile.

Xeomin®

Xeomin® (incobotulinumtoxinA) by Merz Aesthetics® is a boulinum toxin type A that was approved in August, 2010 by the FDA for the treatment of adult cervical dystonia and blepharospasm.  In July, 2011 the FDA approved the product for treatment of glabellar frown lines in adults. Like Dysport®, Xeomin® currently has an FDA-approval for improvement in the appearance of moderate to severe glabellar lines with corrugator and/or procerus muscle activity in adult patients.  Xeomin® is similar to BOTOX® Cosmetic and Dysport® in that it is a type A Botulinum neurotoxin, but unlike both BOTOX® Cosmetic and Dysport®, that are produced in association with ancillary complexing proteins, Xeomin® is made via a proprietary process that isolates the therapeutic component without the ancillary proteins.  This may lessen the likelihood of antibody formation and because of this, it is possible that Xeomin® may be more effective in patients who are resistant to other neuromodulators. The condition known as “injection fatigue” occurs when the duration between treatments becomes shorter and shorter and this may be due to antibody formation against the complexing proteins.  Xeomin® is more like BOTOX® Cosmetic than Dysport® in that it takes about one week for full effect but these three “relaxers” cannot be used interchangeably due to dosing differences.

Why your Dysport® and Xeomin® Experience will be different at Total Aesthetics